Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan
Tsutomu TanakaKazuyuki ShimadaKazuhito YamamotoYoshiki HirookaYasumasa NiwaIsamu SugiuraKunio KitamuraHiroshi KosugiTomohiro KinoshitaHidemi GotoShigeo Nakamura
36
Citation
22
Reference
10
Related Paper
Citation Trend
Keywords:
Univariate analysis
Abstract Background Absolute monocyte count is a poor prognostic factor for a variety of solid tumors and hematological malignancies. However, the importance of monocyte percentage, particularly, in the newly discovered haematological malignancies, is not fully comprehended. So, we analysed the the prognosis role of monocyte percentage at diagnosis in diffuse large B-cell lymphoma (DLBCL). Methods We retrospectively analyzed 169 DLBCL patients who treated with rituximab between 2018 to 2022 and followed at a same hospital. Both univariate analysis and multivariate analysis were performed to investigate the impact of monocyte percentage and clinical characteristics on DLBCL prognosis. Log-rank test analysis appertained to the Kaplan- Meier curve was also conducted to calculated progression-free survival (PFS) and overall survival (OS). Results Among them, there were 53 and 16 cases of disease progression/ relapse and death at the time of follow-up to date, respectively. Using the normal upper limits as the cut-off, we divided monocyte percentage into two group(≤ 10%, > 10%)and low group viewed as reference group. Monocyte percentage were independently related to PFS and OS when monocyte percentage presented as continuous variables in three models. When compared with the reference group, high group has worse PFS (HR 2.54, 95% CI 1.08–5.99, p = 0.033), but no statistical difference was observed in OS in full adjustment model (p = 0.143). The results of Log-rank test suggested that both the PFS and OS of DLBCL patients in the high monocyte percentage group was significantly worse (P < 0.05). Conclusion This cohort study firstly raised a significant association between elevated monocyte percentage and a poor survival outcome.
Monocyte
Cite
Citations (0)
Cutaneous diffuse large B-cell lymphoma, leg type, is a malignant lymphoma of intermediate behavior, occurring mostly on leg(s) of elderly patients. This chapter describes the clinical features, histopathology, immunophenotype, molecular genetics, treatment and prognosis of diffuse large B-cell lymphoma, leg type. It is a matter of discussion whether diffuse large B-cell lymphoma, leg type, is a specific entity per se, or does simply represent a primary cutaneous variant of diffuse large B-cell lymphoma, unspecified. In fact, there are more similarities than differences between these groups, and it has been suggested that diffuse large B-cell lymphoma, leg type, should not be considered as a separate entity, but rather classified within the group of diffuse large B-cell lymphoma, unspecified. It must be remembered that diagnosis of cutaneous diffuse large B-cell lymphoma, leg type, is made only upon negative staging investigations, as any extracutaneous diffuse large B-cell lymphoma may involve the skin secondarily.
Immunophenotyping
Histopathology
Cutaneous lymphoma
Large cell
Cite
Citations (0)
Supplementary Figure Legends 1-2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Rituximab is a human-mouse chimeric monoclonal antibody that has demonstrated efficacy against non-Hodgkin's lymphoma (NHL). There is a powerful rationale for combining rituximab treatment with chemotherapeutic agents that have also shown efficacy in NHL, since the mechanisms of action are distinct and there is also evidence that rituximab may sensitize chemoresistant tumor cells to the actions of cytotoxic drugs. A study of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemoimmunotherapy has been carried out in 40 patients with low-grade NHL. In the 35 patients who completed the study, the overall response rate was 100%, with 63% achieving a complete response. Median time to progression has not yet been reached at 47.2+ months. Molecular analysis (polymerase chain reaction) showed that CHOP plus rituximab (unlike CHOP alone) could completely clear blood and bone marrow of cells containing the bcl-2 gene translocation, a molecular marker of NHL cells. Rituximab can therefore add to the efficacy of CHOP without significantly increasing toxicity. A further study is underway to determine whether similar efficacy with less overall toxicity can be achieved using rituximab in combination with fludarabine.
Chemoimmunotherapy
Cite
Citations (19)
Supplementary Figure Legends 1-2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Cite
Citations (0)
Objective:To compare the efficacy of Rituximab with or without chemotherapy and CHOP alone on newly diagnosed patients with B-cell non-Hodgkin lymphoma(NHL), and to analyze their toxicities.Method:A total of 51 newly diagnosed patients with B-cell NHL were divided into 2 groups prospectively with concurrent control: 24 cases in Rituximab group were administered Rituximab with or without chemotherapy, the remaining 27 cases in CHOP group were treated with CHOP regimen only. All cases were evaluated after 3~6 courses.Result:The complete remission (CR) rate and totol response rate in Rituximab group were 83.3%(20/24) and 95.8%(23/24) respectively, while those corresponding rates in CHOP group were 55.6%(15/27) and 66.7%(18/27), respectively. The therapeutic efficacy differences between two groups showed statistical significance(P0.05). The 2-year overall survival rate was significantly higer in Rituximab group than in CHOP group(70.8% vs. 40.7%, P0.05).Conclusion:Comparing with CHOP group, Rituximab group showed higher therapeutic effects and 2-year overall survival rate. Rituximab can be used with good tolerance.
Regimen
Cite
Citations (0)
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Cite
Citations (0)